The data have been obtained from the Heme Oxygenase Database (HemeOxDB) and refined according to the 2D-QSAR requirements. These data provide information about a set of more than 380 Heme Oxygenase-1 (HO-1) inhibitors. The development of the 2D-QSAR model has been undertaken with the use of CORAL software using SMILES, molecular graphs and hybrid descriptors (SMILES and graph together). The 2D-QSAR model regressions for HO-1 half maximal inhibitory concentration (IC 50 ) expressed as pIC 50 (pIC 50 ¼−LogIC 50 ) are here included. The 2D-QSAR model was also employed to predict the HO-1 pIC 50 values of the FDA approved drugs that are herewith reported.
2D-QSAR model development
2D-QSAR models have been developed with the use of the software CORAL [13] [14] [15] . Once the splits and sets were determined, nine models were developed and statistical quality recorded. Differences of these models consist in the way molecular structures have been depicted for the software process. Thus, in Table 2 regressions for the HO-1 pIC 50 models using SMILES, molecular graphs and hybrid descriptors (SMILES and graph together) are reported. While in Table 3 is reported the statistical quality of models of the HO-1 pIC 50 . Fig. 1 shows a CORAL screenshot with settings for hybrid model split 1. While in Table 4 , the complete list of SMILES and their distribution into the sub-training ( þ), calibration (−), test (#) and validation (*) sets for HO-1 pIC 50 hybrid model split 1 is reported. These data may be prospectively used in finding novel models for HO-1 inhibition. 
2D-QSAR model settings for the best model [hybrid model split 1]

QSAR hybrid model split 1 validation
The endpoints of the FDA-approved drugs were determined in order to additionally validate the model. The whole set composed of 1428 drugs was refined in order to remove quaternary ammonium salts, and compounds with too long SMILES (not elaborated by CORAL), and compounds containing atoms not enumerated in the model (Al, Fe, Gd, etc.). Overall, the whole set was reduced to 1376 compounds and these were evaluated with hybrid model resulting from split 1. Over 1376 compounds, 995 have been defined as outliers by the model since they fall outside the domain of applicability. Table 5 reports the SMILES and predicted HO-1 pIC 50 for these FDA approved drugs evaluated with the hybrid model split 1. 
Table 4
List of SMILES and their distribution into the sub-training ( þ ), calibration (-), test (#) and validation (*) for hybrid model split 1. 
HemeOxDB_ID SMILES
6.046 Table 5 List of SMILES and predicted pIC 50 of the FDA-approved drugs.
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